

Bachem renews supply contract with AstraZeneca

Bubendorf/Basel, 7 February 2017 – The Bachem Group (SIX: BANB) announced today the renewal of its supply agreement with AstraZeneca for the peptide active substance Goserelin. The extended partnership enhances the successful cooperation between both companies. Under the terms of the agreement, AstraZeneca will continue acquiring the peptide active substance Goserelin from Bachem for the next five years. Bachem has been supplying AstraZeneca with Goserelin for more than 25 years.

Dr. José de Chastonay, Chief Marketing Officer of the Bachem Group, commented: “This renewed long-term sales agreement emphasizes the high competitiveness of our products and services. For Bachem, it is also a clear validation of its market position as Pioneering Partner for Peptides. We are delighted about the renewed supply agreement as part of our very successful and long-standing partnership with AstraZeneca.”

About Bachem

Bachem is a listed technology-based company focused on peptide chemistry. The company provides a full range of services to the pharma and biotech industries. It specializes in the development of innovative, efficient manufacturing processes and the reliable production of peptide-based active pharmaceutical ingredients. A comprehensive catalog of biochemicals and exclusive custom syntheses for research labs complete the service portfolio. Headquartered in Switzerland with subsidiaries in Europe and the US, the group has a global reach with more experience and knowhow than any other company in the industry. Towards its customers, Bachem shows total commitment to quality, innovation and partnership.

Bachem. Pioneering Partner for Peptides

For more information:

Bachem Holding AG
Stephan Schindler, CFO
Tel. +41 58 595 2021
Fax: +41 58 595 2043

www.bachem.com
ir@bachem.com